PSTV News and Press, PLUS THERAPEUTICS Inc. From 08/14/23

2023-08-14 16:07:41 ET More on Plus Therapeutics Plus stock rises as radiotherapy shows promise in ongoing brain cancer studies Plus Therapeutics Q3 net loss widens Y/Y Plus Therapeutics jumps 18% as JonesTrading adds another Buy rating Plus Therapeutics fina...

ReSPECT clinical trial data continues to demonstrate promise for treatment of leptomeningeal metastases and recurrent glioblastoma Received FDA approval to move into Phase 1/Part B of the ReSPECT-LM clinical trial Management to host conference call today at 5:00 p.m. ET AU...

2023-08-13 17:35:24 ET Major earnings expected after the bell on Monday include: Suncor Energy ( SU ) Canoo ( GOEV ) Sachem Capital Corp. ( SACH ) Astra Space ( ASTR ) Ayro ( AYRO ) For further details see: Notable earnings after Monday's ...

2023-08-11 17:35:15 ET Plus Therapeutics ( NASDAQ: PSTV ) is scheduled to announce Q2 earnings results on Monday, August 14th, after market close. The consensus EPS estimate is -$2.03 and the consensus revenue estimate is $0.75M. Over the last 3 months, EPS estimates h...

2023-08-11 09:06:20 ET Plus Therapeutics, Inc. ( NASDAQ: PSTV ) up 7% on Friday after it reported positive data from the ReSPECT-LM clinical study evaluating the company’s lead radiotherapeutic, rhenium (( 186 Re)) obisbemeda, for treatment of leptomeningeal me...

Dose escalation trial demonstrates preliminary safety and efficacy results including median overall survival of 10 months for patients with leptomeningeal metastases FDA approves continuation to Phase 1 Part B of the ReSPECT-LM clinical trial Leading academic neuro-oncologists, ...

AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report...

Trial investigators and company management to discuss latest data from the ReSPECT-LM leptomeningeal metastases clinical trial Webinar scheduled for Friday, August 11, 2023 at 8:00 a.m. ET AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: ...

AUSTIN, Texas, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, announced today tha...

AUSTIN, Texas, July 27, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today annou...